All In Biotech

Drug Trial Radar · NCT00942305

Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients

A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Jul 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 239 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

239

Actual

Start

Oct 2009

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
Jul 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study of brincidofovir (BCV) administered orally once or twice weekly for up to 11 weeks. Dosing was initiated immediately following engraftment (between Days 14-30 post-transplant) to prevent/control cytomegalovirus (CMV) infection or prevent disease in R+ hematopoietic stem cell transplant (HCT) recipients.

Conditions

  • Cytomegalovirus Infection

Interventions

  • BrincidofovirDrug

    Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.

  • PlaceboDrug

    Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant. Matching placebo administered for each cohort.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Clinically Significant CMV InfectionTime frame: Randomization to Week 8 post-treatment (~19 weeks)

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Moores UCSD Cancer Center

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • University of Colorado Denver

    Aurora, Colorado

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Brigham and Womens Hospital, Division of Infectious Disease

    Boston, Massachusetts

  • University of Michigan Medical School

    Ann Arbor, Michigan

  • Harper University Hospital

    Detroit, Michigan

  • University of Minnesota Medical Center

    Minneapolis, Minnesota

  • Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mt. Sinai School of Medicine

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Montefiore Medical Center Oncology

    The Bronx, New York

  • UNC Health Care Center

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • The Cleveland Clinic

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Baylor University Medical Center

    Dallas, Texas

  • UT Southwestern Medical Center at Dallas

    Dallas, Texas

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists - Intermountain Healthcare

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.